Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098504 | 0.95 | HSP90AA1 (1.00) | HSP90AA1 | |
| SCHEMBL4096545 | 0.94 | HSP90AA1 (0.88) | HSP90AA1 | |
| SCHEMBL4092201 | 0.91 | HSP90AA1 (0.92) | HSP90AA1 | |
| SCHEMBL4091595 | 0.91 | HSP90AA1 (0.84) | HSP90AA1 | |
| SCHEMBL4096219 | 0.91 | HSP90AA1 (0.91) | HSP90AA1 | |
| SCHEMBL4092522 | 0.90 | HSP90AA1 (0.86) | HSP90AA1 | |
| SCHEMBL4096136 | 0.90 | HSP90AA1 (0.89) | HSP90AA1 | |
| SCHEMBL4085780 | 0.90 | HSP90AA1 (1.00) | HSP90AA1 | |
| SCHEMBL4102077 | 0.90 | HSP90AA1 (0.90) | HSP90AA1 | |
| SCHEMBL4093505 | 0.90 | HSP90AA1 (0.90) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036895-B9 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-07-10 | — | — | EP | claimed |
| EP-2036895-B1 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-16 | — | — | EP | claimed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | claimed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | claimed |
| EP-4630004-A1 | TREATMENT OF PROSTATE CANCER HAVING ANDROGEN RECEPTOR VARIANTS | Oric Pharmaceuticals, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250305055-A1 | PROGNOSTIC/PREDICTIVE BREAST CANCER SIGNATURE | CORNELL UNIVERSITY | 2025-10-02 | — | — | US | disclosed |
| US-12427192-B2 | Water soluble adjuvant and composition containing same | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-30 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250263669-A1 | INDUCED TOTIPOTENT STEM CELLS AND PREPARATION METHOD THEREFOR | UNIV TSINGHUA (CN) | 2025-08-21 | — | — | US | disclosed |
| US-12383608-B2 | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides | Sumitomo Pharma Co., Ltd. (JP) | 2025-08-12 | — | — | US | disclosed |
| WO-2025122992-A1 | CELLULAR ANCESTRY SIGNATURES FOR SUBTYPING CANCERS PRIORITY | CORNELL UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| US-12281301-B2 | Sequencing-based proteomics | THE BROAD INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-2036895-A1 | HSP90 INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-03-18 | — | — | EP | disclosed |
| EP-2036895-A1 | HSP90 INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383608-B2 | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides | KLK3, TAP1, KLHL6 | HSP90AA1 1506/4885 |
| US-20090247524-A1 | HSP90 Inhibitor | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885 |
| US-12427192-B2 | Water soluble adjuvant and composition containing same | TP53, MYD88, AQP1 | HSP90AA1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.